Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
KHK4951 Phase 2 Results Expected
KHK4951 • Neovascular Age-Related Macular Degeneration (nAMD)
Target Indication
Neovascular Age-Related Macular Degeneration (nAMD)
Clinical Trial
NCT06116890Last updated: 12/4/2025